Novo Nordisk

In late July 2026, Novo Nordisk reported that its late-stage ZEUS trial for the anti-inflammatory drug ziltivekimab did not meet its primary goal, prompting inv...

Key Points Shares of Danish drugmaker Novo Nordisk fell nearly 10% today. The drop came after an experimental cardiovascular drug failed a late-stage clinical...

In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) crossed below their 200 day moving average of $106.41, changing hands as low as $106.29 per share...

Monte Rosa Therapeutics (GLUE) is trading lower after Novo Nordisk’s (NVO) ZEUS trial failed to show a cardiovascular benefit for IL 6 inhibition, a readout tha...

Key Points Both companies are giants in diabetes and obesity treatments. Lately, Eli Lilly has moved ahead in the obesity segment. Things could change, howev...

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today . Novo pre-announ...

William Blair analyst Andy Hsieh said the results from Novo Nordisk’s ZEUS trial cast doubt on the link between large reductions in high-sensitivity C-reactive...

Shares of Novo Nordisk tumbled on Friday after the healthcare giant said that a drug it was developing to treat heart disease, kidney disease and inflammation f...

Novo Nordisk A/S (NYSE:NVO) stock plunged on Friday after the company announced disappointing headline results from its ZEUS Phase 3 cardiovascular outcomes tri...

A failed late stage heart drug trial at Novo Nordisk, with shares in Copenhagen down 8.6% and U.S. ADRs down 9.8% in premarket trading, has pushed cardiovascula...